DIADIA1.84%
SPYSPY1.93%
QQQQQQ3.64%
Trending
Top trending tickerNASANASA18.31%
CRWVCRWV6.80%
NBISNBIS13.08%
RKLBRKLB18.05%
ADBEADBE11.45%
RDWRDW23.87%
VELOVELO43.25%
GLXYGLXY11.28%
ALABALAB19.99%
PWRL35.70%
Top trending tickerNASANASA18.31%
CRWVCRWV6.80%
NBISNBIS13.08%
RKLBRKLB18.05%
ADBEADBE11.45%
RDWRDW23.87%
VELOVELO43.25%
GLXYGLXY11.28%
ALABALAB19.99%
PWRL35.70%
homeSymbolPRLDnews
PRLD logo

PRLDPrelude Therapeutics Inc

$4.11
$0.16
(4.05%)
Today
Closed $4.11
$0.2262
(5.50%)
After Hours
Updated: 04:33 PM EDT
EarningsAug 13
Mkt Cap$314.6M
Vol204,867.00
54

Neutral Sentiment

How do you feel about PRLD?

Feed

News

Sentiment

Earnings

Fundamentals

Info

News
all
press releases
Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 33.6% in Prelude Therapeutics (PRLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
News Placeholder
More News
News Placeholder
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Given Consensus Recommendation of "Hold" by Analysts
Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) has earned an average rating of 'Hold' from the five brokerages that are presently covering the stock, Marketbeat.com reports. One...
MarketBeat
News Placeholder
Prelude Therapeutics (NASDAQ:PRLD) Coverage Initiated by Analysts at D. Boral Capital
D. Boral Capital initiated coverage on shares of Prelude Therapeutics in a research note on Monday. They set a 'buy' rating and a $9.00 price target on the stock...
MarketBeat
News Placeholder
Prelude Therapeutics (NASDAQ:PRLD) Rating Increased to Hold at Zacks Research
Zacks Research raised Prelude Therapeutics to a "hold" rating in a research report on Tuesday...
MarketBeat
News Placeholder
Prelude Therapeutics (PRLD) Expected to Announce Quarterly Earnings on Tuesday
Prelude Therapeutics (NASDAQ:PRLD) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-5-prelude-therapeutics-incorporated-stock...
MarketBeat
News Placeholder
HC Wainwright Issues Positive Forecast for Prelude Therapeutics (NASDAQ:PRLD) Stock Price
HC Wainwright upped their price objective on shares of Prelude Therapeutics from $5.00 to $8.00 and gave the stock a "buy" rating in a report on Monday...
MarketBeat
News Placeholder
Insider Buying: Prelude Therapeutics (NASDAQ:PRLD) Director Acquires 2,815,315 Shares of Stock
Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) Director Orbimed Advisors Llc acquired 2,815,315 shares of the business's stock in a transaction on Tuesday, April 21st. The shares...
MarketBeat
News Placeholder
Prelude Therapeutics (NASDAQ:PRLD) Director Buys $12,499,998.60 in Stock
Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) Director Orbimed Advisors Llc acquired 2,815,315 shares of Prelude Therapeutics stock in a transaction that occurred on Tuesday, April 21st. The stock was purchased at an average cost of $4.44 per share, with a total value of...
MarketBeat
News Placeholder
Prelude Therapeutics (NASDAQ:PRLD) Director David Bonita Buys 2,815,315 Shares
Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) Director David Bonita bought 2,815,315 shares of Prelude Therapeutics stock in a transaction on Tuesday, April 21st. The stock was acquired at an average cost of $4.44 per share, for a total transaction of $12,499,998.60. Following...
MarketBeat
News Placeholder
Prelude Therapeutics Appoints Charles Morris As Chief Medical Officer
(RTTNews) - Prelude Therapeutics Incorporated (PRLD), a clinical-stage precision oncology company, said on Wednesday that Charles Morris will join the company as chief medical officer with effect from April 20...
Nasdaq News: Markets
<
1
2
...
>

Advertisement|Remove ads.

Advertisement|Remove ads.